ascopubs.org

The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration ...

Radium-223 for mCRPC, a real-world experience study from 7 Galician medical centers. This is an ASCO Meeting Abstract from the 2023 ASCO Genitourinary Cancers Symposium. This abstract does not include ...
ascopubs.org

Homologous recombination repair (HRR) mutation concordance between liquid biopsy (LB) and tumor tissue by NGS in a real-world prostate cancer (PC) database.

Tumor transcriptomic profile in patients (pts) with advanced prostate cancer (PCa) with cribriform and signet ring-like histologies. Genomic, clinical characteristics, and treatment outcomes of ...
The American Journal of Managed Care

Patients With BRCA-Mutated mCRPC Show Worse Outcomes vs Non-BRCA HRR mCRPC

An analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) deficiency mutations showed that patients with BRCA mutations had poor ...
Cure Today

FDA Updates Talzenna-Xtandi Label for HRR-Mutated Metastatic Prostate Cancer

The FDA approved updated labeling for Talzenna plus Xtandi for HRR gene-mutated metastatic castration-resistant prostate cancer, based on the TALAPRO-2 trial results. The TALAPRO-2 trial showed a ...
The Manila Times

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone ...

AMPLITUDE is the first clinical trial to evaluate potential therapies for patients with mHSPC and known HRR gene alterations, with positive results supporting the niraparib-based combination regimen a ...